The IMPAACT Network is a cooperative group of institutions, investigators, and other collaborators focused on evaluating potential therapies for HIV infection and its related symptoms in infants, children, adolescents, and pregnant women, including clinical trials of HIV/AIDS interventions for and prevention of mother-to-child transmission.
The IMPAACT Network resulted from the merger of two predecessor networks: the Pediatric AIDS Clinical Trials Group and the perinatal scientific working group of the HIV Prevention Trials Network. It is co-funded by the NICHD Maternaland Pediatric Infectious Disease Branch (MPIDB) (formerly the Pediatric, Adolescent, and Maternal AIDS Branch) and the National Institute of Allergy and Infectious Diseases, and receives funding from other NIH Institutes and Offices, including the National Institute of Mental Health.
As an international project, the IMPAACT Network includes both a domestic research agenda and an international research agenda. The domestic research agenda includes a focus on evaluating the pharmacokinetics, safety, optimal dosing, and long-term complications of new antiretroviral (ARV) therapies for HIV/AIDS in pediatric and adolescent populations, among other topics and activities. The international research agenda includes a focus on the prevention of mother-to-child transmission of HIV and reduction of maternal and infant morbidity and mortality from HIV/AIDS through studies such as Promoting Maternal and Infant Survival Everywhere (PROMISE). A new focus is on prevention of HIV acquisition by adolescent girls in low and middle-income countries.
The IMPAACT Network collaborates with the NICHD Domestic and International Pediatric/Maternal HIV Clinical Studies Network, the Adolescent Medicine Trials Network for HIV/AIDS Interventions, and with other NICHD-, NIH-, and organization-led HIV/AIDS research networks and projects.
As of 2014, the Network included:
- 6 domestic and 18 international Clinical Research Sites (CRSs) funded by NIAID and 15 domestic and 14 international sites funded by NICHD through the NICHD Domestic and International Pediatric and Maternal HIV Clinical Studies Network , for a total of 21 domestic and 29 international sites where clinical trials are conducted
- Statistical and Data Management Center (SDMC) to manage and coordinate data
- Leadership and Operations Center that provides the overall scientific and administrative leadership for the Network
- Laboratory Center that leads development, implementation and evaluation of the laboratory research conducted within the Network
- IMPAACT Community Advisory Board (ICAB), which enables communities to provide input and feedback on Network activities
The IMPAACT Network conducts clinical trials of HIV/AIDS therapy, prevention, and potential remission/cure in maternal, pediatric, and adolescent patients. Current Network studies include (but are not limited to) the following:
- A randomized trial (PROMISE) comparing various antenatal and postnatal strategies of preventing mother-to-child transmission of HIV in different geographical areas and resource settings
- A clinical trial to determine whether women with CD4 counts above the country threshold for initiation of antiretroviral therapy should continue or discontinue ARV therapy after pregnancy
- A study of the pharmacokinetics and safety of ARV drugs in pregnant HIV-infected women
- Several pharmacokinetic studies to evaluate interactions between ARV drugs and anti-malarial medications, anti-tuberculosis medications, and psychiatric medications
- Several studies evaluating the safety and efficacy of different vaccines in HIV-infected children, including rotavirus, meningococcal, parainfluenza, human papillomavirus, and anti-tuberculosis vaccines
- Studies to evaluate the pharmacokinetics and safety of drugs to treat complications of HIV or its treatment, including atorvastatin to treat hyperlipidemia associated with ARV drugs and alendronate to treat low bone mineral density in infected children
- Studies of new ARV drugs, such as raltegravir, etravirine, and the new integrase inhibitor dolutegravir, in infants, children, and adolescents
- Studies to evaluate the pharmacokinetics of ARV drugs in HIV-infected children with special conditions such as malnutrition or prematurity
- Strategies for the treatment of infected children with multi-class drug failure
- Strategies for very early treatment of HIV-infected neonates and its effect on viral reservoir and potential for remission of HIV
Visit the IMPAACT Network Web site for more details.